Testing effectiveness (Phase 2)Study completedNCT01320085
What this trial is testing
A Phase II Study of Single Agent MEK162 in Patients With Advanced Melanoma
Who this might be right for
BRAF or NRAS Mutant Metastatic Melanoma
Pfizer 183
Showing 2 of 2 results